Mr. Hsu is the founder and chairman of Rayliant Global Advisors, a professor of finance at University of California at Los Angeles (UCLA), and on the Board of Advisors for UCLA Anderson School of Management. Rayliant is an asset manager focused on generating alpha from investing in China and other inefficient emerging markets, which has a total of USD 27 billion of investment assets using its strategies across equity, fixed income and alternatives.
Prior to founding Rayliant, Mr. Hsu was the co-founder and Chief Investment Officer of Research Affiliates, a quantitative fund manager with over $200 billion under management. Mr. Hsu has received 3 JPM Fabozzi-Bernstein Outstanding Research Awards, 3 CFA Institute Graham and Dodd awards, 3 William Sharpe Best Research awards, 2010 Rising Star of Hedge Fund, 40+ Journal publications and 11+ books and book chapters on investing, 2009 Outstanding Service Award (UCLA Anderson), and has held visiting positions at UC Irvine, National Taiwan Chengchi University, Kyoto University and Tsinghua University.
Mr. Hsu received his BS (summa cum laude) from the California Institute of Technology, was awarded a MS from Stanford University, and earned his PhD in finance from UCLA.
What is Jason Hsu's net worth?
The estimated net worth of Jason Hsu is at least $7.45 million as of July 18th, 2024. Hsu owns 816,200 shares of Immix Biopharma stock worth more than $7,447,825 as of March 26th. This net worth estimate does not reflect any other assets that Hsu may own. Learn More about Jason Hsu's net worth.
How do I contact Jason Hsu?
Has Jason Hsu been buying or selling shares of Immix Biopharma?
Jason Hsu has not been actively trading shares of Immix Biopharma in the last ninety days. Most recently, on Wednesday, July 24th, Jason Hsu bought 6,000 shares of Immix Biopharma stock. The stock was acquired at an average cost of $2.15 per share, with a total value of $12,900.00. Following the completion of the transaction, the director now directly owns 822,200 shares of the company's stock, valued at $1,767,730. Learn More on Jason Hsu's trading history.
Who are Immix Biopharma's active insiders?
Are insiders buying or selling shares of Immix Biopharma?
In the last twelve months, Immix Biopharma insiders bought shares 6 times. They purchased a total of 11,019 shares worth more than $30,275.04. The most recent insider tranaction occured on December, 10th when CEO Ilya M Rachman bought 746 shares worth more than $4,975.82. Insiders at Immix Biopharma own 55.4% of the company.
Learn More about insider trades at Immix Biopharma. Information on this page was last updated on 12/10/2025.
